Industry Working Group finalizes cell-collection labeling standards for cell and gene therapies to improve patient safety

Cell and gene therapies have shown promise in their ability to cure and heal patients rather than merely treat their symptoms. The emerging sector is growing so quickly that the development of some standards has lagged behind. In September 2019, Deloitte launched the NextGen Therapy Industry Working Group (IWG) to develop labeling standards for cells collected for cell and gene therapy (CGT) manufacturing. After a little more than a year, the voluntary group has drafted.
Read more...

;